Liver biopsy: Evolving role in the new millennium

Journal of Clinical Gastroenterology

Volumn 39, Issue 7, 2005, Pages 603-610

  Sheela, Harinath ^a   Seela, Srinivas ^a   Caldwell, Cary ^a   Boyer, James L ^a   Jain, Dhanpat ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic hepatitis; Contraindication; Indications; Liver biopsy; NASH; Role

Indexed keywords

ALCOHOL LIVER DISEASE; AUTOIMMUNE HEPATITIS; CHRONIC HEPATITIS; DIAGNOSTIC TEST; HEMOCHROMATOSIS; HEPATITIS C; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER DISEASE; NEEDLE BIOPSY; NONALCOHOLIC FATTY LIVER; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TECHNIQUE;

BIOPSY; HUMANS; LIVER; LIVER DISEASES; SENSITIVITY AND SPECIFICITY;

EID: 23044503358     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000170742.59134.60     Document Type: Review

References (57)

1. von Frerichs FT. Uber den Diabetes. Berlin: Hirschwald, 1884.
2. Menghini G. One-second needle biopsy of the liver. Gastroenterology. 1958;35:190-199.
3. Brady PG, Peebles M, Goldschmid S. Role of laparoscopy in the evaluation of patients with suspected hepatic or peritoneal malignancy. Gastrointest Endosc. 1991;37:27-30.
4. Angtuaco TL, Lal SK, Banaad-Omiotek GD, et al. Current liver biopsy practices for suspected parenchymal liver diseases in the United states: the evolving role of radiologists. Am J Gastroenterol. 2002;97:1468-1471.
5. Lindor KD, Bru C, Jorgensen RA, et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology. 1996;23:1079-1083.
6. Janes CH, Lindor KD. Outcome of patents admitted with complications after outpatient liver biopsies. Ann Intern Med. 1993;118:96-98.
7. Pasha T, Gabriel S, Therneau T, et al. Cost-effectiveness of ultrasound-guided liver biopsy. Hepatology. 1998;27:1220-1226.
8. Riley TR III. How often does ultrasound marking change the liver biopsy site? Am J Gastroenterol. 1999;94:3320-3322.
9. Bateson MC, Hopwood D, Duguid HL, et al. A comparative trial of liver biopsy needles. J Clin Pathol. 1980;33:131-133.
10. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449-1457.
11. Glimore IT, Burroughs A, Murray-Lyon IM, et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal college of Physicians of London. Gut. 1995;36:437-441.
12. Sorbi D, Dougulas B, Mc Gill JL, et al. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterology. 2000;95:3206-3210.
13. WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec. 1997;72:341-344.
14. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States. 1988 through 1994. N Engl J Med. 1999;341:556-562.
15. Kyrlagkitis I, Portmann B, Smith H, et al. Liver histology and progression of fibrosis in individual with chronic hepatitis C and persistently normal ALT. Am J Gastroenterol. 2003;98:1588-1593.
16. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology. 1997;26 (suppl):57-61.
17. Poynard T, Marcellin P, Lee SS, et al. Randomized trail of interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus: International hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426-1432.
18. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
19. As Yu, Keeffe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord. 2002;2:11-19.
20. Daniel S, Ben-Menachem T, Vasudevan G, et al. Prospective evaluation of unexplained chronic liver transaminases abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol. 1999;94:3010-3014.
21. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol. 2001;35:195-199.
22. Brunt EM, Tetri N, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;35:1202-1219.
23. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liv Dis. 2001;21:3-16.
24. Trousseau A. Glycosurie, diabete, sucre, In: Clinique Medicale del'Hotel-Dieu de Paris, vol.2, ed 2. Paris: Balliere, 1865:663.
25. Von Recklinghausen FD. Uber Hamochromatose. Tagebl Vesammi Nautyr Arzte Heidelberg. 1889;62:324.
26. Simon M, Bourel M, Genetet B, et al. Idiopathic hemochromatosis: demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med. 1977;29:1017-1021.
27. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class 1-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399-408.
28. Bodnier JG, Parham P, Albert ED, et al. For the WHO Nomenclature Committee for Factors of the HLA System: putting a hold on 'HLA-H.' Nat Genet. 1997;15:234-235.
29. Scheuer PJ, Wiliams R, Muir AR. Hepatic pathology in relatives of patients with hemochromatosis. J Pathol Bacteriol. 1962;84:53-64.
30. Deugnier YM, Turlin B, Powell L, et al. Differentiation between heterozygotes and homozygotes in genetic hemochromatosis by means of a histological hepatic iron index: a study of 192 eases. Hepatology. 1993;19:30-34.
31. Brunt EM, Olynyk JK, Britton RS, et al. Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Am J Gastroenterol. 2000;95:1788-1793.
32. Kowdely KV, Trainer TD, Saltzman JR, et al. Utility of hepatic iron index in American pateints with hereditary hemochromatosis: a multicenter study. Gastroenterology. 1997;113:1270-1277.
33. Press RD, Flora K, Gross C, et al. Hepatic iron overload: direct HFE (HLA-H) mutation analysis vs quantitative iron assays for the diagnosis of hereditary hemochromatosis. Am J Clin Pathol. 1998;109:577-584.
34. Bacon BR, Olynyk JR, Brunt EM, et al. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med. 1999;130:953-962.
35. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 115:929-936.
36. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology. 1999;33:1321-1328.
37. Kowdley KV, Hassanein T, Kaur S, et al. Primary liver cancer and survival in hereditary hemochromatosis patients undergoing orthotopic liver transplantation. Liver Transplant Surg. 1995;1:237-241.
38. Burak KW, Angulo P, Lindor KD. Is there a role of liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol. 2003;98:1155-1158.
39. Kim WR, Therneau T, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75:688-694.
40. Talley NJ, Roth JA, Hench WV. Diagnostic value of liver biopsy in alcoholic liver disease. J. Clin Gastroenterolo. 1988;10:647-650.
41. Levin DM, Baker AL, Riddell RH, et al. Nonalcoholic liver disease: overlooked causes of liver injury in patients with heavy alcohol consumption. Am J Med. 1979;66:429-434.
42. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938.
43. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci. 1981;26:388-393.
44. Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: how safe is it? Ann Intern Med. 1993;118:150-153.
45. Perrault J, McGill DB, Ott BJ, et al. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology. 1978;74:103-106.
46. Rosson RR, Corral J, Jaski T. Outpatient liver biopsy. JAMA. 1972;222:364.
47. Piccinino F, Sagnelli E, Pasquale G. Complications following percutaneous liver biopsy: a multicenter retrospective study on 68,276 biopsies. J Hepatol. 1986;2:165-173.
48. Marano BJ, Bonanno AC. Liver biopsy in patient's with AIDS. Am J Gastroenterol. 1993;110:2139.
49. Gordon SC, McFadden RF, Reddy KR. Major hemorrhage after percutaneous liver biopsy in patients with AIDS. Amer J Gastro. 1991;100:1787.
50. Scoazec JY, Marche C, Garard PM, et al. Pleosis hepatis and sinusoidal dilation during infection human immunodeficiency virus (HIV): an ultrastructural study. Am J Pathol. 1988;131:38-47.
51. Zakaria N, Kinsley A, Portman B, et al. Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy. Blood. 2003;101:101-103.
52. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. Gut. 1999;45(suppl IV):1-11.
53. Van Leewan DJ, Wilson L, Crowe DR. Liver biopsy in the mid-1990s: questions and answers. Semin Liver Dis. 1995;15:340-359.
54. Spycher C, Zimmermann A, Relchen J. The diagnostic value of liver biopsy. BMC Gastroenterol. 2001;1:12.
55. Gilmore IT, Burroughs A, Murray-Lyon IM, et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut. 1995;36:437-441.
56. Schiff ER, Schiff L. Needle biopsy of the liver. In: Schiff L, Schiff ER, eds. Disease of the Liver. Philadelphia: Lippincott, 1993.
57. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495-500.